Adicet Bio Promotes Blake Aftab to Chief Scientific Officer
4:21PM ET 10/12/2021 MT NewswiresAdicet Bio (ACET) said late Tuesday it promoted Blake Aftab to chief scientific officer. Aftab has served as vice president and head of research at the...
Quotes Snapshot > ACET
Adicet Bio Inc ACET:NASDAQ
Last Price$9.80NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$8.00 (10)
Ask (Size)$9.80 (1)
Day Low / HighN/A - N/A
Volume273.6 K
Read more news Recent News
Adicet Bio Teams Up With Twist Bioscience to Boost Discovery of Cancer Therapies
10:05AM ET 9/13/2021 MT NewswiresAdicet Bio (ACET) and Twist Bioscience (TWST) have formed a collaboration to develop gamma delta T cell cancer-fighting therapies against five key targets,...
Insider Trends: Insider Prolongs 90-Day Selling Trend at Adicet Bio
4:27PM ET 6/21/2021 MT NewswiresChen Schor, Director and President & CEO, sold 16,466 shares in Adicet Bio (ACET) for $173,443 on Jun 16, 2021. Subsequent to the Form 4 filing with the...
Insider Trends: 90-Day Insider Selling Trend Continued at Adicet Bio
7:14PM ET 6/07/2021 MT NewswiresChen Schor, Director and President & CEO, sold 16,466 shares in Adicet Bio (ACET) on Jun 03, 2021, for $198,499. Schor, after the transactions described...
View all Commentary and Analysis
Adicet Bio (ACET) Investor Presentation - Slideshow
10:23AM ET 8/13/2021 Seeking AlphaWeek 17 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge
7:08AM ET 4/25/2021 Seeking AlphaLAVA Therapeutics Seeks $101 Million U.S. IPO
1:30PM ET 3/22/2021 Seeking AlphaAdicet Bio (ACET) Investor Presentation - Slideshow
4:27AM ET 2/28/2021 Seeking AlphaCompany Profile
Business DescriptionAdicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA. View company web site for more details
| Address | 500 Boylston Street Boston, Massachusetts 02116 |
| Phone | +1.857.315.5528 |
| Number of Employees | 21 |
| Recent SEC Filing | 11/18/2021 4 |
| President, CEO, Secretary & Director | Chen Schor |
| Chief Financial Officer | Brian Nicholas Harvey |
| Chief Medical Officer & Senior Vice President | Francesco Galimi |
| Chief Technology Officer | Donald Healey |
Company Highlights
| Price Open | $10.45 |
| Previous Close | $10.35 |
| 52 Week Range | $6.25 - 17.80 |
| Market Capitalization | $313.2 M |
| Shares Outstanding | 32.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/10/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$2.05 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -570.14% |
| Return on Equity | -27.86% |
Analyst Ratings as of 05/17/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |